General Information of the Drug (ID: M6APDG03829)
Name
OMP-18R5
Synonyms
Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals
    Click to Show/Hide
Status
Phase 1
TTD Drug ID
D00GPY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Frizzled-7 receptor (FZD7)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
Response Summary Frizzled-7 receptor (FZD7) is a therapeutic target for OMP-18R5. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OMP-18R5 through regulating the expression of Frizzled-7 receptor (FZD7). [1], [2]
References
Ref 1 YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7. Cancer Res. 2021 May 15;81(10):2651-2665. doi: 10.1158/0008-5472.CAN-20-0066. Epub 2020 Aug 11.
Ref 2 Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci. 2010 Jul;99(7):3100-21. doi: 10.1002/jps.22087.